BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28447160)

  • 1. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes.
    Rottmann M; Burges A; Mahner S; Anthuber C; Beck T; Grab D; Schnelzer A; Kiechle M; Mayr D; Pölcher M; Schubert-Fritschle G; Engel J
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1833-1844. PubMed ID: 28447160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
    Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
    Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer.
    Tanner EJ; Long KC; Feffer JB; Leitao MM; Abu-Rustum NR; Barakat RR; Chi DS; Gardner GJ
    Gynecol Oncol; 2013 Jan; 128(1):28-33. PubMed ID: 23017819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube.
    Sehouli J; Olschewski J; Schotters V; Fotopoulou C; Pietzner K
    Ann Oncol; 2013 Dec; 24(12):3024-8. PubMed ID: 24130264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.
    Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB
    Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology--a prospective comparative study.
    Schnack TH; Sørensen RD; Nedergaard L; Høgdall C
    Gynecol Oncol; 2014 Nov; 135(2):278-84. PubMed ID: 25168689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.
    Wethington SL; Herzog TJ; Seshan VE; Bansal N; Schiff PB; Burke WM; Cohen CJ; Wright JD
    Cancer; 2008 Dec; 113(12):3298-306. PubMed ID: 19006196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases.
    Sun M; Bao L; Shen H; Ji M; Yao L; Yi X; Jiang W
    Taiwan J Obstet Gynecol; 2019 Sep; 58(5):626-632. PubMed ID: 31542083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study.
    Lu CH; Chen IH; Chen YJ; Wang KL; Qiu JT; Lin H; Lin WC; Liou WS; Huang YF; Lin YS; Tee YT; Hung YC
    Int J Gynecol Cancer; 2014 Mar; 24(3):506-12. PubMed ID: 24557435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Factors in Patients Undergoing Primary Cytoreductive Surgery for FIGO Stage IIIC Ovarian, Tubal or Peritoneal Cancer.
    Kaban A; Topuz S; Saip P; Sözen H; Salihoğlu Y
    J Obstet Gynaecol Can; 2018 Apr; 40(4):447-453. PubMed ID: 29055648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
    Leandersson P; Hogberg T; Dickman PW; Malander S; Borgfeldt C
    BMC Cancer; 2021 Apr; 21(1):465. PubMed ID: 33902507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the added value of hospital-registry data for showing local service outcomes: cancers of the ovary, fallopian tube and peritoneum.
    Roder D; Davy M; Selva-Nayagam S; Paramasivam S; Adams J; Keefe D; Miller C; Powell K; Fusco K; Buranyi-Trevarton D; Oehler MK
    BMJ Open; 2019 Feb; 9(2):e024036. PubMed ID: 30782891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
    Sørensen RD; Schnack TH; Karlsen MA; Høgdall CK
    Gynecol Oncol; 2015 Mar; 136(3):571-81. PubMed ID: 25615934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data.
    Barclay M; Gildea C; Poole J; Hirschowitz L; Menon U; Nordin A
    Int J Gynecol Cancer; 2016 Jan; 26(1):56-65. PubMed ID: 26509852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.
    Ataseven B; Chiva LM; Harter P; Gonzalez-Martin A; du Bois A
    Gynecol Oncol; 2016 Sep; 142(3):597-607. PubMed ID: 27335253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.